(E)-N-(5-methyl-1,2-oxazol-3-yl)-3-(3,4,5-trimethoxyphenyl)prop-2-enamide

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: (E)-N-(5-methyl-1,2-oxazol-3-yl)-3-(3,4,5-trimethoxyphenyl)prop-2-enamide
• 化学式: C₁₆H₁₈N₂O₅
• 分子量: 318.32
• InChiKey: CJFOLSDEJYREKV-AATRIKPKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  23
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  82.8
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• METHODS OF TREATING OCULAR DISORDERS
  申请人：Beta Therapeutics Pty. Ltd.

  公开号：EP3554505A1

  公开（公告）日：2019-10-23
• Methods of Treating Ocular Disorders
  申请人：NELMS Keats

  公开号：US20200093852A1

  公开（公告）日：2020-03-26

  This invention relates to the use of a heparanase inhibitor for treating, or inhibiting the progression or development of, an ocular inflammatory disorder, such as age-related macular degeneration, diabetic retinopathy, retinitis pigmentosa, retinal 5 vein occlusion, retinoblastoma, uveitis, macular edema, dry eye, ocular inflammation associated with an infection or keratoconus.
• [EN] METHODS OF TREATING OCULAR DISORDERS<br/>[FR] MÉTHODES DE TRAITEMENT DE TROUBLES OCULAIRES
  申请人：BETA THERAPEUTICS PTY LTD

  公开号：WO2018107226A1

  公开（公告）日：2018-06-21

  This invention relates to the use of a heparanase inhibitor for treating, or inhibiting the progression or development of, an ocular inflammatory disorder, such as age- related macular degeneration, diabetic retinopathy, retinitis pigmentosa, retinal 5 vein occlusion, retinoblastoma, uveitis, macular edema, dry eye, ocular inflammation associated with an infection or keratoconus.